A conflict of interest is defined as "a set of conditions in which professional judgment concerning a primary interest (such as a patient's welfare or the validity of research) tends to be unduly influenced by a secondary interest (such as financial gain)" [Thompson DF. Understanding financial conflicts of interest. N Engl J Med 1993;329(8):573-576]. Because financial conflict of interest (fCOI) can occur at different stages of a study, and because it can be difficult for investigators to detect their own bias, particularly retrospectively, we sought to provide funders, journal editors and other stakeholders with a standardized tool that initiates detailed reporting of different aspects of fCOI when the study begins and continues that reporting throughout the study process to publication. We developed a checklist using a 3-phase process of pre-meeting item generation, a stakeholder meeting and post-meeting consolidation. External experts (n = 18), research team members (n = 12) and research staff members (n = 4) rated or reviewed items for some or all of the 7 major iterations. The resulting Financial Conflicts of Interest Checklist 2010 consists of 4 sections covering administrative, study, personal financial, and authorship information, which are divided into 6 modules and contain a total of 15 items and their related sub-items; it also includes a glossary of terms. The modules are designed to be completed by all investigators at different points over the course of the study, and updated information can be appended to the checklist when it is submitted to stakeholder groups for review. We invite comments and suggestions for improvement at www.openmedicine.ca/fcoichecklist and ask stakeholder groups to endorse the use of the checklist.
A conflict of interest is defined as "a set of conditions in which professional judgment concerning a primary interest (such as a patient's welfare or the validity of research) tends to be unduly influenced by a secondary interest (such as financial gain)." 1 Conflict of interest in biomedical research is a complex issue that has received a great deal of attention. The focus of the 2009 Institute of Medicine report on conflict of interest highlights the importance of this issue. 2 When there are financial interests in research studies there is concern that these relationships may influence research outcomes. 3 Despite the importance of this issue, there is considerable variability in the way that these relationships have been reported. 2, 3 To protect research participants and maintain public trust in research, it is important that potential financial conflicts of interest (fCOIs) are disclosed and steps are taken, where indicated, to manage their effects. 2 Investigators may not always recognize their own potential conflicts of interest and therefore would benefit from a structured method of documenting and reporting fCOI to stakeholders for assessment purposes. 2, 4 When we began this project in January 2007, various fCOI reporting disclosures were required by different stakeholder groups such as funders, 5 academic institutions, 6 and journal editors. 7 These disclosures were not coordinated and were typically collected using different reporting formats (e.g., fCOI forms, fCOI statements). This meant that investigators might need to complete multiple different conflict of interest reporting disclosures for their study in order to meet the needs of different stakeholders.
We sought to provide stakeholders with a single structured checklist that contains detailed information about different aspects of fCOI. Further, we placed this information within the context of a specific clinical research study to facilitate assessment of the potential impact of the financial relationship on the research. By using a prospective format, potential conflicts can be identified at an early stage in the research process and managed where required. The checklist is initiated when the study begins and is updated throughout the study process to publication. Although we designed the checklist for clinical research studies, we recognize that other types of studies have the potential to be influenced by fCOIs.
Developing the Financial Conflicts of Interest

Checklist 2010
We developed the checklist using a 3-phase process of pre-meeting item generation, a stakeholder meeting, and post-meeting consolidation. This process, shown in Figure 1 , was adapted from one described in a recent report on developing health research reporting guidelines. 8 Contributors to the development of this checklist are listed in the Acknowledgments.
Pre-meeting item generation. The checklist items were generated initially by our research team, whose members have expertise in research, ethics boards, law and policy, trial registration, research administration, clinical research and research guideline developmentspecifically the Consolidated Standards of Reporting Trials (CONSORT) and Enhancing QUAlity and Transparency Of health Research (EQUATOR) Network-and were based primarily on the published literature. We identified potential items from international initiatives targeting specific aspects of fCOI. For example, items related to trial registration were derived from the World Health Organization trial registration initiative, 9 and items related to roles in manuscripts were drawn from the International Committee of Medical Journal Editors (ICMJE) guidelines on authorship in medical publishing 4, 7 and the World Association of Medical Editors guidelines on authorship. 10 After compiling an initial list of 15 items and 92 subitems, we reviewed it using 3 groups: external experts (n = 18) with expertise in trial registration, research guideline development (CONSORT, EQUATOR), ethics review, government administration policy, health law, medical journals and media; members of the research team (n = 12); and members of our research staff (n = 4). Research staff members were included to provide a perspective from non-experts with experience in the research process.
Reviewers were asked to rate the importance of each of the items using a 5-point scale (1 = least important, 5 = most important) and to provide free-text suggestions for improving them. On the basis of these responses, we developed a second version of the checklist and, 1 month later, sent it to the participants for review. Not all of the reviewers were available for both rating sessions: 29 provided feedback to version 1, and 24 provided feedback to version 2.
Stakeholder meeting.
A total of 28 people participated in a day-long stakeholder meeting in October 2007 in Toronto, Ontario, Canada. In attendance were 11 research team members and 4 research staff; 13 external experts participated using web-teleconference connections from 4 countries. We presented draft version 3 of the checklist for item discussion and identified areas for revision. The meeting was organized into 4 thematic sessions reflecting the requirements and concerns of major stakeholder groups (clinical trial registry users, journal editors, funders and policymakers, and legal and ethics review board representatives). Each external expert participated in 1 session based on his or her area of expertise. Each session began with an overview of the checklist project, followed by a description of the particular thematic area; the session chair then led a discussion focusing on items that received discrepant ratings in the premeeting reviews.
Post-meeting consolidation. The post-meeting consolidation phase involved 3 steps. First, the research team incorporated the changes suggested at the stakeholder meeting into draft version 4 of the checklist-including dividing the items into modules-and then pilot-tested this version for usability with a small group of 6 investigators. We also created an example document showing examples of good reporting, an explanation document providing evidence and rationales for the items, and an interactive PDF version of the checklist.
Second, the research team met in Toronto for a 1-day consolidation meeting in March 2009 and reviewed the checklist by module and item. We reworded and reorganized items for greater clarity, decided to create a glossary to facilitate shared understanding and usage of key terms used in the items, and discussed how to improve the usability of the PDF version. We also had further discussions on how we envisioned the checklist would be implemented in practice.
In the third step of the post-meeting consolidation phase, we incorporated the most recent changes into draft version 5 of the checklist. Definitions for the glossary terms were 
Revisions for consistency and clarity
MWDesign incorporated as roll-over pop-ups attached to the terms in the PDF. We revised the corresponding example and explanation documents and pilot-tested the checklist again for usability. After successive revisions for consistency and clarity to the draft version 6 checklist and the corresponding interactive PDF, version 7 of the Financial Conflicts of Interest Checklist 2010 was created. Ethical review and approval of the checklist process was obtained from the Baycrest Centre and Women's College Research Institute Ethics Board, where the principal investigator was located.
The Financial Conflicts of Interest Checklist 2010
The Financial Conflicts of Interest Checklist 2010 (Table  1) consists of a 15-item form and a glossary of terms with definitions derived from sources obtained from our literature review. The checklist is also available as an interactive PDF (see the online Appendix). A feature of the PDF format is that it uses "skip logic"; it presents to investigators only selections relevant to them at the time of checklist completion based on their answers. The glossary is incorporated into the PDF through pop-ups that provide the definition when a mouse rolls over a glossary term.
The 4 sections of the checklist cover administrative information, study information, personal financial information and authorship information. These sections are divided into 6 modules containing a total of 15 items and their related sub-items. The Administrative Information section contains module A, which compiles administrative information about the study and investigator, and the date(s) when the checklist was first filled out and subsequently updated. The Study Information section contains modules B to D, which create a funder profile, contract profile, and study team and funder relationship profile respectively. The Personal Financial Information section contains module E, which creates a financial profile for each investigator of the study and author of any study publication. Finally, the Authorship Information section contains module F, which creates an authorship profile for each author involved in manuscript preparation. We have also provided an example document ( Table  2) , which presents examples of good reporting, and an explanation document (Box 1), which presents rationales and evidence for each of the 6 modules.
The checklist was designed as a living document that is updated as the study progresses. In general, sections 1 to 3 will be completed at study initiation and updated as necessary (for example, section 3, the Personal Financial Information section, would require updating if the investigator's financial profile changed); section 4 will be completed when a manuscript is being prepared for publication. We anticipate that updated information would be appended to the originally completed checklist to maintain a permanent record of information related to fCOI throughout the course of the study.
We recognize that clinical research and, in particular, clinical trials are generally conducted by a team of investigators. We recommend that each investigator independently complete the entire checklist. When the checklist is submitted to a stakeholder for review, the person most knowledgeable about the study, such as the overall study official (in the case of clinical trials) or study guarantor (in the case of a manuscript submission), would collate sections of the checklist that have shared information (i.e., module A: Administrative Profile, module B: Funder Profile and module C: Contract Profile).
We pilot-tested the checklist twice during the postmeeting consolidation phase. Of the 17 participants in these usability surveys, 13 (76%) had served as an investigator in a randomized trial. Eleven (65%) respondents reported no difficulty in answering the questions. Although the checklist should be completed at different stages of the study process, for the purposes of determining usability respondents were asked to estimate the time required to complete the entire checklist: 16 (94%) required less than 20 minutes.
Discussion
We have created a checklist that aims to promote transparency at all stages of the research and publication process. An important feature of our checklist is that, as a record completed by investigators as the study evolves, it can be given to the various stakeholders who are involved at different stages of the clinical research process-funding agencies, research ethics boards, trial registries, research administrators and journal editors-which is a more consistent, efficient and effective approach than providing each group with separate, disjointed disclosures. As well, since the type of fCOI information required by stakeholders varies substantially, use of the checklist may help standardize the information.
Prospective completion of the checklist means that there is an ability to elicit fCOI disclosures throughout the study's "life stages" (e.g., from study inception to dissemination) and to maintain a public record of this information for its duration. There are 2 benefits to identifying potential fCOI situations at an early stage. First, it allows appropriate management to minimize harms; for example, the situation can be referred to a conflict of interest committee. The Institute of Medicine report Conflict of interest in medical research, education, and practice 2 outlines steps for identifying and responding to such a committee. Second, it leads to more accurate reporting of fCOI. Investigators may be in an fCOI situation while they are conducting a study but divest themselves of it by the time they are submitting the study results for publication; such an fCOI may not be readily apparent to journal editors. The ICMJE recently published a new disclosure form for competing interests that is completed by authors at the end of a study, during the publication phase. 11 The form is used by journal editors, and consensus for the form's use has been built among all ICMJE journals. Given that the disclosure is occurring at the end of the research process, the opportunity to intervene and manage the fCOI is lost.
The checklist may have an educational role in that it is designed to be completed by each investigator. We recognize that clinical research is generally conducted by a team of investigators. When all investigators are asked to complete the entire checklist, irrespective of their role in the study, they will become sensitized to important issues about their study. Academic policies do not always provide investigators with clear guidance to assist them in identifying and reporting situations that may be relevant to fCOI. Further, national surveys of fCOI policies in academic settings suggest that these policies are often incomplete, 6, 12, 13 fragmented 12 and difficult for investigators to understand, 12, 14 all of which limit their practical usability by investigators. Although the checklist will likely initially be completed by investigators only, it is also relevant to other study team members who may be affected by fCOI, such as study coordinators, research assistants and study nurses.
The checklist has been designed so that a completed version can be attached along with a completed CON-SORT checklist in the setting of a clinical trial. 15 The checklist can have an application beyond clinical research studies, and we anticipate that it will be adapted for use for other types of studies, such as basic science research. It can also be adapted for use outside of the research setting. For example, modified versions could be completed by grant review panel members making funding decisions, guideline panel members making decisions about best practices, board members making decisions about the direction of an academic organization, and by expert witnesses providing expert opinions in court proceedings or tribunals. Accordingly, we designed the checklist with sections, modules and items so that it can be tailored for use in a range of settings.
The checklist has limitations. First, our checklist was designed to focus exclusively on financial conflicts of interest. We recognize that there are non-financial conflicts of interest, but these are known to be difficult to define. 16 Financial conflicts of interest are the most well recognized and the most quantifiable. 1 Second, although there are only 15 items, some users may feel daunted by the detail requested in a few of the sub-items. Our pilot testing revealed a checklist completion time of less than 20 minutes. Importantly, the entire checklist need not-and likely should not-be completed at one time. As we have recommended, different modules should be completed at different stages of the research. As users become more familiar with the checklist, and become aware of the information it compiles, the time required to complete it will likely decrease. In any case, the checklist can serve as a useful repository of essential administrative information, and the time taken to complete the checklist may be considered a worthy investment in ensuring accurate and transparent disclosure of fCOI.
Conclusion
We developed the checklist to help investigators report comprehensive structured information about fCOI to multiple stakeholder groups. We invite comments and suggestions for adaptations and improvement of the next iteration of the checklist at www.openmedicine.ca/fcoi-at www.openmedicine.ca/fcoichecklist. We also call for stakeholder groups to endorse the use of this checklist to improve transparency and mitigate fCOI in clinical research.
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The Financial Con icts of Interest Checklist 2010 was designed to be completed by each investigator in the context of a speci c clinical research study. As awareness of nancial con ict of interest issues grows, we see the checklist being completed by other study team members, such as study coordinators, research assistants and study nurses.
This checklist contains four sections: administrative information, study information, personal nancial information, and authorship information. The investigator is expected to complete the checklist prospectively as the clinical research moves through its various stages. Sections 1, 2 and 3 are rst lled out at the study's initiation, updated as required, and completed when the study manuscript is submitted for publication; section 4 is also completed at this time.
SECTION 2: STUDY INFORMATION
This section is completed at the study's initiation and updated as necessary. 
MODULE B: FUNDER PROFILE
❑ Yes ❑ No ❑ Don't know ______________________________________ ❑ Yes ❑ No ❑ Yes ❑ No ❑ Yes ❑ No ❑ Yes ❑ No ❑ Yes ❑ No ❑ Yes ❑ No ❑ Don't know ❑ Yes ❑ No ❑ Yes ❑ No ❑ Yes ❑ No ❑ Yes ❑ No ______ days❑ Study team ❑ Funder ❑ Shared § ❑ Don't know ❑ Study team ❑ Funder ❑ Shared § ❑ Don't know ❑ Study team ❑ Funder ❑ Shared § ❑ Don't know ❑ Study team ❑ Funder ❑ Shared § ❑ Don't know ❑ Study team ❑ Funder ❑ Shared § ❑ Don't know ❑ Study team ❑ Funder ❑ Shared § ❑ Don't know ❑ Study team ❑ Funder ❑ Shared § ❑ Don't know ❑ Study team ❑ Funder ❑ Shared § ❑ Don't know ❑ Study team ❑ Funder ❑ Shared § ❑ Don't know ❑ Study team ❑ Funder ❑ Shared § ❑ Don't know ❑ Study team ❑ Funder ❑ Shared § ❑ Don't know ❑ Study team ❑ Funder ❑ Shared § ❑ Don't know ❑ Study team ❑ Funder ❑ Shared § ❑ Don't know ❑ Study team ❑ Funder ❑ Shared § ❑ Don't❑ Yes ❑ No ______________________________________ ❑ Yes ❑ No ❑ Yes ❑ No ❑ Yes ❑ No ❑ Yes ❑ No ❑ Yes ❑ No ❑ Yes ❑ No ❑ Yes ❑ No ❑ Yes ❑ No ❑ Yes ❑ No ❑ Yes ❑ No ❑ Yes ❑ No ❑ Yes ❑ No ❑ Yes ❑ No ❑ Yes ❑ No ______________________________________ ______________________________________
SECTION 4: AUTHORSHIP INFORMATION
This section is completed when a manuscript is being submitted for publication. To which aspects of the study and the manuscript development did you make a substantial contribution?
MODULE F: AUTHORSHIP PROFILE
F.2.1a
Obtaining funding ‡
F.2.1b
Conceptualizing and designing the study*
F.2.1c
Providing study materials and/or recruiting participants ‡
F.2.1d
Collecting or assembling data*
F.2.1e
Analyzing and interpreting data*
F.2.1f
Providing statistical expertise ‡
F.2.1g
Supervising or coordinating the study ‡
F.2.1h
Drafting all or part of the manuscript*
F.2.1i
Revising the manuscript for important intellectual content*
F.2.1j
Giving nal approval of the version to be published* 
Financial interest
Anything of monetary value, including but not limited to: Ghost author " Ghost authorship exists when someone has made substantial contributions to writing a manuscript and this role is not mentioned in the manuscript itself. "
-World Association of Medical Editors 10
Guarantor " The person who takes responsibility for the integrity of the work as a whole, from inception to published article, and publishes that information"
-International Committee of Medical Journal Editors 1
Guest author " Guest authorship is the practice of inviting those whose contribution has been scienti cally trivial to be coauthors, as payment for a service (e.g. referral of a patient) or as tribute (e.g., homage to a department head). The practice of guest authorship is deceptive because the 'authors' so named gather credit without being able to account for the work. "
- Rennie et al. 11 Overall study o cial "Person(s) responsible for the overall scienti c leadership of the protocol, including study principal investigator"
-ClinicalTrials.gov 12 To which aspects of the study and the manuscript development did you make a substantial contribution?
For more information about the Financial Con icts of Interest Checklist 2010 and to download or ll out a PDF of the checklist, go to www.openmedicine.ca/fcoichecklist
F.2.1a
F.2.1b
F.2.1c
F.2.1d
F.2.1e
F.2.1f
F.2.1g
F.2.1h
F.2.1i
F.2.1j
Giving final approval of the version to be published* Guarantor " The person who takes responsibility for the integrity of the work as a whole, from inception to published article, and publishes that information" -InternationalCommitteeofMedicalJournalEditors 1
Guest author " Guest authorship is the practice of inviting those whose contribution has been scientifically trivial to be coauthors, as payment for a service (e.g. referral of a patient) or as tribute (e.g., homage to a department head). The practice of guest authorship is deceptive because the 'authors' so named gather credit without being able to account for the work. "
-Rennieetal. 11
Overall study official "Person(s) responsible for the overall scientific leadership of the protocol, including study principal investigator"
-ClinicalTrials.gov 12
INTRODUCTION
The Financial Con icts of Interest Checklist 2010 was designed to be completed by each investigator in the context of a speci c clinical research study. As awareness of nancial con ict of interest (fCOI) issues grows, we see the checklist being completed by other study team members, such as study coordinators, research assistants and study nurses.
SECTION 1: ADMINISTRATIVE INFORMATION This section is completed at the study's initiation and updated as necessary
This module compiles administrative information about the study and the investigator lling out the checklist. Administrative information helps characterize the study and place it in context.
Identifying the countries involved in data collection for a speci c clinical trial provides an opportunity to evaluate the standards in place for the ethical conduct of trials across sites. 1, 2 Information about clinical trial registration is included to promote accountability and transparency of research. Trial registration helps mitigate the potential impact of fCOI by publicly documenting important protocol information before a study begins and participants are enrolled. Two decades ago Chalmers described the serious problem of underreporting of clinical trials that occurs when results are either published in insu cient detail or not published at all, and he advocated for trial registration. 3 A more recent systematic review has shown that underreporting of clinical trials continues to be an issue. 4 This has important implications for clinical practice because it means that the body of published articles may exaggerate the e ectiveness of a given therapy.
The International Committee of Medical Journal Editors (ICMJE) requires registration for trials published in journals that adhere to ICMJE standards. 5 The World Health Organization's International Clinical Trials Registry Platform was established in 2005 to create global standards for trial registration. 6 Further, trial registration and results reporting are now required by law in the United States. 7 Information is requested about the role that each individual completing the checklist will play in the study's conduct. This informs stakeholders about the extent to which he or she is involved in the study and provides a perspective on the level of knowledge and responsibility the investigator will have of the study. An overall study o cial will have a comprehensive understanding of all of the key issues related to the organization of the study. Other investigators may have more limited knowledge about certain aspects of the study.
SECTION 2: STUDY INFORMATION This section is completed at the study's initiation and updated as necessary
Module B: Funder Pro le
This module compiles information about all of the sources of funding for the study.
Research studies receive funding from di erent sources. Information in this module is requested about funders from categories including industry, government, charitable foundations and others. Financial con icts of interest can occur with a range of di erent funders. Con icts of interest related to the conditions of the funding have the potential to in uence research ndings. 8, 9 Industry funding is important to consider because 70% of clinical drug trial funding in the US is estimated to be from industry sources, 10 and a quarter of academic investigators in biomedical research are estimated to receive industry funding for their research. 11 Accordingly, reporting of funding sources is relevant in assessing possible fCOI.
Module C: Contract Pro le This module addresses contracts with funders and is lled out by investigators who have received a contract for the study.
Contracts vary depending on the institution, the nature of the study, and the funder. Considerable concern has been expressed about restrictive con dentiality clauses, 12, 13, 14 which can be used to delay or prevent study information from being made public and thereby interfere with the publication of negative results or unfavourable data. 14 Investigators need to retain the right to decide on publication of the study results to ensure that the study results contribute to publicly available knowledge. ICMJE supports the sponsor's right to review a manuscript before it is published but suggests a de ned time of 30-60 days to allow for the ling of additional patent protection. 15 One academic organization suggests extending the time to 90 days, and in exceptional cases to as long as 6 months. 12 
